Literature DB >> 180274

Respiratory syncytial virus infections in infants: quantitation and duration of shedding.

C B Hall, R G Douglas, J M Geiman.   

Abstract

Infants hospitalized with respiratory syncytial virus infection were studied to delineate the quantitative shedding patterns and duration of shedding of RSV. Nasal wash specimens collected daily from 19 infants contained a mean maximal titer of 4.34 log10 50% tissue culture infective doses per milliliter. On admission, the mean titer was 4.14 log10 TCID50, with no consistent decline until after Day 6. The mean duration of shedding for 23 patients until they were virus negative was 6.7 days with a range of 1 to 21 days. Quantities of RSV shed were significantly greater in infants less than one month of age and in infants with evidence of pulmonary consolidation on chest roentgenogram. Shedding extended for a significantly longer time in infants with lower respiratory tract disease than in those with clinical manifestations limited to the upper respiratory tract.

Entities:  

Mesh:

Year:  1976        PMID: 180274     DOI: 10.1016/s0022-3476(76)80918-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  81 in total

1.  Airway IFN-γ production during RSV bronchiolitis is associated with eosinophilic inflammation.

Authors:  Chang Keun Kim; Zak Callaway; Young Yull Koh; Soo-Hee Kim; Takao Fujisawa
Journal:  Lung       Date:  2011-12-13       Impact factor: 2.584

Review 2.  The respiratory syncitial virus and its role in acute bronchiolitis.

Authors:  M L Everard; A D Milner
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

3.  Latent sensitisation to respiratory syncytial virus during acute bronchiolitis and lung function after recovery.

Authors:  S J Caswell; A H Thomson; S P Ashmore; C S Beardsmore; H Simpson
Journal:  Arch Dis Child       Date:  1990-09       Impact factor: 3.791

4.  Virus-inducible expression of a host chemokine gene relies on replication-linked mRNA stabilization.

Authors:  T Koga; E Sardiña; R M Tidwell; M Pelletier; D C Look; M J Holtzman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

5.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

6.  Prolonged viral replication and longitudinal viral dynamic differences among respiratory syncytial virus infected infants.

Authors:  Monica E Brint; Joshua M Hughes; Aditya Shah; Chelsea R Miller; Lisa G Harrison; Elizabeth A Meals; Jacqueline Blanch; Charlotte R Thompson; Stephania A Cormier; John P DeVincenzo
Journal:  Pediatr Res       Date:  2017-08-09       Impact factor: 3.756

7.  Diagnostic performance of a rapid antigen test for RSV in comparison with a 19-valent multiplex RT-PCR ELISA in children with acute respiratory tract infections.

Authors:  Heike Schützle; Josef Weigl; Wolfram Puppe; Johannes Forster; Reinhard Berner
Journal:  Eur J Pediatr       Date:  2007-09-02       Impact factor: 3.183

8.  The cotton rat (Sigmodon hispidus) is a permissive small animal model of human metapneumovirus infection, pathogenesis, and protective immunity.

Authors:  John V Williams; Sharon J Tollefson; Joyce E Johnson; James E Crowe
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Detection of human metapneumovirus antigens in nasopharyngeal secretions by an immunofluorescent-antibody test.

Authors:  Takashi Ebihara; Rika Endo; Xiaoming Ma; Nobuhisa Ishiguro; Hideaki Kikuta
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

10.  Detection of respiratory syncytial virus (RSV) antigen in the lungs of guinea pigs 6 weeks after experimental infection and despite of the production of neutralizing antibodies.

Authors:  H J Streckert; S Philippou; F Riedel
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.